ArticleFrontiers in oncology2025
Clinical study on bronchial artery chemoembolization for unresectable non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07738367 (A Single-Arm Phase II Study of Bronchial Artery Chemoembolization), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm Phase II Study of Bronchial Artery Chemoembolization (BACE) Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Without Standard Treatment Options
Who cites it
2 citing papers in PubMed.
- Improved early response assessment of chemoimmunotherapy efficacy byEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy of Bronchial Artery Infusion/Chemoembolization Combined with Platinum-Based Chemotherapy and PD-1 Inhibitor in Initially Unresectable Stage III Non-Small Cell Lung Cancer.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the efficacy and safety of bronchial artery chemoembolization (BACE) for the treatment of inoperable non-small cell lung cancer (NSCLC). Methods: A retrospective review was conducted of 112 patients with NSCLC who received BACE treatment and 120 patients who underwent systemic chemotherapy in our center over the past 10 years. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), quality of life, and adverse events were compared between the two groups. Results: The complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates in the BACE group were 7.14%, 39.29%, 33.04%, and 20.54%, respectively, while those rates in the chemotherapy group were 7.5%, 20.83%, 55.0%, and 16.67%. The ORR in the BACE group was significantly higher than in the chemotherapy group (46.43% vs. 28.33%, Conclusion: BACE treatment for inoperable NSCLC offers better clinical outcomes compared to systemic chemotherapy and is safe and well-tolerated, with no severe adverse events. This approach warrants further prospective randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.